

## REFERENCES

1. Foote FW, Stewart FW. Lobular carcinoma in situ: A rare form of mammary cancer. *The American journal of pathology*. 1941;17(4):491-6 3. Epub 1941/07/01.
2. Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. *Archives of pathology & laboratory medicine*. 2010;134(7):1024-8. Epub 2010/07/01.
3. Rosen PP. *Rosen's breast pathology*. 3 ed: LIPPICORT WILLIAMS & WILKINS; 2009; 637 – 87.
4. Hwang ES NS, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. *Cancer*. 2004;100(12):2562-72. Epub 6 May 2004.
5. Acs G LT, Rebbeck TR, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biological and diagnostic implications. *American journal of clinical pathology*. 2001;115:85 - 9.
6. Goldstein NS BD, Watts JC, et al. E-Cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. *American journal of clinical pathology*. 2001;115:534-42.
7. Jacobs TW PN, Kouria G, et al. . Carcinomas in situ of the breast with indeterminate features. Role of E-cadherin staining in categorization. *The American journal of surgical pathology*. 2001;25:229-36.
8. Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. *The American journal of surgical pathology*. 2009;33(11):1683-94. Epub 2009/08/25.
9. Murray L, Reintgen M, Akman K, Cox C, Cox J, Reintgen D, et al. Pleomorphic Lobular Carcinoma in Situ: Treatment Options for a New Pathologic Entity. *Clinical breast cancer*. 2011. Epub 2011/11/01.

10. Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. *The American journal of surgical pathology*. 2010;34(10):1472-9. Epub 2010/09/28.
11. Dabbs DJ BR, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. *The American journal of surgical pathology*. 2007;31(3):427-37.
12. Acs G LT, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. *American journal of clinical pathology*. 2001;115:85-98.
13. CD LN, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. *Cancer letters*. 1978;42:737 - 69.
14. Sneige N WJ, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2002;15:1044-50.
15. PP. R. The pathological classification of human mammary carcinoma: Past, present and future. *Annals of clinical and laboratory science*. 1979;9:144-56.
16. PP. R. Lobular carcinoma in situ and intraductal carcinoma of the breast. McDivitt RW OH, Ozzello L, Kaufman N, editor. Baltimore: Williams and Wilkins; 1984.
17. Lechner MD PS, Jackman RJ, et al. Lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous biopsy with surgical correlation : A multi-institutional study. *Radiology*. 1999;213:106.
18. Foster MC HM, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? *Radiology*. 2004;231:813-9.
19. Crisi GM MS, Cronin E, et al. Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. *The American journal of surgical pathology*. 2003;27:325-33.

20. MA. C. Cancer upgrades at excisional biopsy after diagnosis of atypical lobular hyperplasia or lobular carcinoma in situ at core-needle core biopsy: Some reasons why. *Radiology*. 2004;231:621-71.

## APPENDIX

**Table 1.** Type of lesion from 176 cases between 2006 – 2010, Maharaj Nakorn Chiang Mai Hospital

Type	Number of the cases (%)
LCIS / ID	6 (3.4%)
LCIS / IL	6 (3.4%)
LCIS / ID+IL	1 (0.6%)
LCIS+DCIS / ID	4 (2.3%)
LCIS+DCIS / IL	0 (0.0%)
LCIS+DCIS / ID+IL	2 (1.1%)
DCIS pure	43 (24.4%)
DCIS / ID	109 (61.9%)
DCIS / IL	3 (1.7%)
DCIS / ID+IL	2 (1.1%)

**Note :** LCIS = Lobular carcinoma in situ, DCIS = Ductal carcinoma in situ, IL = Invasive lobular carcinoma, ID = Invasive ductal carcinoma

**Table 2.** E-cadherin staining in each type of lesion

TYPE	E-cadherin staining				
	Negative (%)	Focal staining (%)	Focal loss (%)	Faint staining (%)	Positive staining (%)
<b>DCIS</b>					
Comedo	0	0	0	3 (12.5%)	21 (87.5%)
Combined only	0	0	2 (2.9%)	5 (7.2%)	62 (89.9%)
Non comedo + combined (% within DCIS)	0	0	0	26 (38.8%)	41 (61.2%)
<b>LCIS</b>					
Classical	7 (43.8%)	5 (31.3%)	4 (25%)	0	0
Pleomorphic (% within LCIS)	0	2 (66.7%)	1 (33.3%)	0	0

**Note :**

**Negative :** no staining

**Focal staining :** positive staining in small number of the tumor cells

**Focal loss :** positive in most of the tumor cells

**Faint staining :** weakly positive staining in all tumor cells

**Positive staining :** positive staining in all tumor cells

## CURRICULUM VITAE



**Name** Miss Suchanan Rattanasalee

**Date of Birth** November 17, 1984

**Graduate** Doctor of Medicine  
Faculty of Medicine, Chiang Mai University,  
Chiang Mai, Thailand

**Position** Residency Training in Anatomical Pathology  
Department of pathology  
Faculty of Medicine  
Chiang Mai University  
Chiang Mai, 50200, Thailand  
Tel: (053) 94-5442

